Actively Recruiting
Precision Medicine for L/GCMN and Melanoma 1 (Precis-mel 1)
Led by Fundacion Clinic per a la Recerca Biomédica · Updated on 2025-02-28
6000
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
F
Fundacion Clinic per a la Recerca Biomédica
Lead Sponsor
H
Hospital Clinic of Barcelona
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are creating a comprehensive database for melanoma that includes children, adolescents, and young adults along with adult patients. This database aims to analyze survival rates and evaluate sentinel lymph node positivity in younger patients. The study also focuses on adapting existing precision medicine algorithms for younger populations, using transfer learning to improve models with limited pediatric data, and integrating expert medical opinions into the decision support system. Artificial intelligence will be used to develop models that predict melanoma outcomes across all age groups. The study uses retrospectively collected data including demographic, genetic, medical procedures, cancer treatments, and biopsy information to build a detailed dataset. Advanced data engineering techniques will organize the data into a model-ready format that preserves patient history over time. The team will apply Gradient Boosting Survival Analysis, a specialized machine learning method for survival data, to handle censored information and estimate survival probabilities. Model performance will be evaluated using the concordance index, which measures how well predicted outcomes match actual events. Participants' medical records from adults and younger patients will be included, with 6,000 adult melanoma cases and 120 cases from children, adolescents, and young adults. Researchers will analyze survival curves and sentinel lymph node positivity over a 24-month period. Data integrity is maintained through identifiers connecting patient events, and different transformations enrich the dataset. This observational study does not involve any direct treatment but focuses on data analysis to improve melanoma prognosis models.
CONDITIONS
Brief Title
Precision Medicine for L/GCMN and Melanoma 1
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Melanoma patients of any age with histopathological confirmed melanoma
You will not qualify if you...
- Not having a melanoma diagnosis
- Not having signed the informed consent
- Records prior to the year 2012 (as data might not accurately reflect current practices and treatment outcomes)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for eligibility confirmation and consent
Duration - Data collection spanning records from 2012 onwards
Participants’ existing medical data, including demographic, genetic, and treatment records, are collected retrospectively for analysis.
No visits required; data collection is retrospective
Duration - Up to 24 months
Participants’ prognosis and survival data are analyzed over time using advanced statistical models.
No visits required; ongoing data analysis from existing records
Trial Site Locations
Total: 1 location
1
Hospital Clínic de Barcelona (Dermatology service)
Barcelona, Catalonia, Spain, 08036
Actively Recruiting
Research Team
S
Susana Puig Sardà, MD, PhD
A
Adrián López Canosa, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here